Denali Therapeutics (DNLI) Operating Income (2017 - 2026)
Denali Therapeutics (DNLI) reported Operating Income of -$137.4 million for Q1 2026, up 5.65% year-over-year from -$130.0 million in Q1 2025, and little changed quarter-over-quarter from -$137.4 million in Q4 2025.
Denali Therapeutics (DNLI) Operating Income (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has 10 years of Operating Income data on file, last reported at -$137.4 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$137.4 million, up 5.65% year-over-year; the trailing twelve-month figure through Mar 2026 was -$547.1 million (down 6.19% YoY), and the FY2025 annual result was -$555.3 million, down 13.95% from the prior year.
- Operating Income was little changed at -$137.4 million in Q1 2026 per DNLI's latest filing, from -$137.4 million in the prior quarter.
- Over five years, Operating Income peaked at $170.5 million in Q2 2023 and troughed at -$145.6 million in Q1 2025.
- A 5-year average of -$101.0 million and a median of -$120.8 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2024: Operating Income jumped 377.59% in 2023, then slumped 168.39% in 2024.
- A 5-year view of Operating Income shows it stood at -$105.3 million in 2022, then retreated by 25.85% to -$132.6 million in 2023, then climbed by 2.06% to -$129.8 million in 2024, then declined by 5.79% to -$137.4 million in 2025, then advanced by 0.01% to -$137.4 million in 2026.
- Business Quant data shows DNLI's Operating Income at -$137.4 million in Q1 2026, -$137.4 million in Q4 2025, and -$137.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Denali Therapeutics | 4.35 Bn | 4.35 Bn | - | -137.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -137.36 Mn |
| Dec 31, 2025 | -137.37 Mn |
| Sep 30, 2025 | -137.43 Mn |
| Jun 30, 2025 | -134.96 Mn |
| Mar 31, 2025 | -145.58 Mn |
| Dec 31, 2024 | -129.85 Mn |
| Sep 30, 2024 | -123.19 Mn |
| Jun 30, 2024 | -116.59 Mn |
| Mar 31, 2024 | -117.72 Mn |
| Dec 31, 2023 | -132.57 Mn |
| Sep 30, 2023 | -113.80 Mn |
| Jun 30, 2023 | 170.48 Mn |
| Mar 31, 2023 | -120.82 Mn |
| Dec 31, 2022 | -105.34 Mn |
| Sep 30, 2022 | -107.49 Mn |
| Jun 30, 2022 | -61.42 Mn |
| Mar 31, 2022 | -66.50 Mn |
| Dec 31, 2021 | -77.12 Mn |
| Sep 30, 2021 | -85.59 Mn |
| Jun 30, 2021 | -61.82 Mn |